Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

Top 10 Breast Cancer Trials to Watch at #ASCO25 Save the date ⏰ Big data in HER2+, TNBC & HR+ mBC! 1️⃣ DESTINY-Breast09 – T-DXd+P vs THP (1L HER2+ MBC) [LBA] 2️⃣ ASCENT-04 – SG+pembro vs chemo+pembro (1L TNBC) [LBA] 3️⃣ SERENA-6 – Camizestrant+CDK4/6i in ESR1mut HR+ ABC [LBA] 4️⃣

🚨Save the date🚨 ASCO #IMG Community of Practice Meeting at #ASCO25 ⏰May 30st, 4-6 PM CST 📌Room S103, McCormick Place Join us to discuss barriers & opportunities for IMGs ASCO IMG CoP👉bit.ly/3JmJQwK The ASCO Post #IMGoncCoP #MedEd #MedTwitter

I heard the nicest line from a colleague a few days ago as to how to introduce a regimen with many adverse events to practicing oncologists: “This regimen will offer you a great opportunity to collaborate with your subspecialist colleagues”…

Heading to #ASCO25 for the first time as a trainee? It can be overwhelming but also incredibly rewarding! Here’s some honest advice I wish I’d had as a resident/fellow. 👇 What are YOUR top tips for first-timers? Share & RT!

Genetic blood test for cancer screening of healthy individual With no family history of cancer is how precision Oncology is abused . It is called as Shot gun 🔫 oncology.

Interesting read!

Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. ja.ma/3SjdWpr

An exceptional new NEJM review on cancer of unknown origin nejm.org/doi/full/10.10…

Thanks for sharing!

Poster session now 🔥 ❤️ ICI associated myocarditis 130,234 pts ✅0.49% risk - majority happens in the first year of ICI initiation; especially the first three months ‼️Risk factors: age>65, HTN, HLD, melanoma, and ipilimumab use Appreciate Lei Deng, MD (He/Him) for your mentorship #ASCO25

📢 #ASCO25: In pts w/ 5–20 brain mets, SRS/SRT led to fewer symptoms & less functional interference vs HA-WBRT, w/ similar OS (~8.4 mo). 🔬 Phase 3 RCT (n=196) 💡 SRS/SRT = new SoC for brain mets >4? meetings.asco.org/abstracts-pres… #RadOnc #NeuroOnc #SRS #WBRT #BrainMets

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Great (free) article in ASCO Educational Book on innovations and best practices for AI use in oncology and clinical trials by UCSD Fellow Tali Azenkot ; ascopubs.org/doi/pdf/10.120…

Another way to frame the question: If a pharmaceutical company could sell exercise as a drug—given its well-established efficacy and safety—how would it be priced? 15k per month?

Do we have any MRD (minimal residual doubt) that MRD assays will make a major impact in risk stratification in periop/peri-xrt patient management? The plot thickens as to their clinical value/utility!

📢 Now Online! Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC. Grateful to all the co-authors 🔗 Full article here: doi.org/10.1016/j.lung… #NSCLC #immunotherapy #lungcancer

The next generation of immunotherapies for lung cancers Although there are many drugs currently in development, my current favorites are ivonescimab (PD-1 × VEGF) and tarlatamab (DLL3 × CD3). 💥Even better ones are yet to come nature.com/articles/s4157…

Cancer vaccines will be a big part of the future of immunotherapy. A new, super review The Lancet thelancet.com/journals/lance…

Oxaliplatin in Stage II–III CRC: Age Matters 🔹 Stage III, ≤70 yrs → OS benefit 🔹 Stage III, >70 yrs → No OS gain 🔹 Stage II (any age) → No OS benefit 💬 Supports an individualized, age- and stage-adapted approach to adjuvant oxaliplatin use jamanetwork.com/journals/jaman…